Gleneagles's parent company establishes AI lab to drive medical innovation 

Gleneagles Hospital Hong Kong’s parent company, IHH Healthcare North Asia, has launched an Artificial Intelligence Laboratory (AI Lab) in Hong Kong, initially focusing on local collaborative projects to drive medical innovation.

These include partnerships with the University of Hong Kong to develop AI-based remote heart and lung auscultation tools and AI-powered risk prediction systems for heart diseases.

The lab is also engaging with other academic institutions, such as the Hong Kong University of Science and Technology (HKUST), Hong Kong Baptist University (HKBU), and the Hong Kong Polytechnic University (PolyU), as well as medtech startups.

Potential collaborations span various fields, including AI-driven smart clinic solutions, innovative diagnostic technologies, and remote monitoring and telemedicine platforms.

Currently, the lab has already initiated projects with two HKUST-incubated startups and a partner of HKBU. These include implementing smart clinic solutions at Gleneagles MediCentre, set to launch in late 2025, and applying emerging viral diagnostics technology to the hospital’s laboratory and telemedicine services.

The medical group stated that the lab will serve as a hub for cutting-edge AI technologies, fostering collaboration between academia, startups, and tech firms to advance medical innovation.

As the lab expands, it will explore partnerships with innovation and technology organizations beyond Hong Kong.

“We believe that innovation and technology are not just tools but transformative forces essential to addressing rising patient needs and delivering smarter, more efficient, and personalized care,” said Kenneth Tsang, Regional CEO of IHH and CEO of Gleneagles Hong Kong.

(Cheng Wong)